BIOXYNE LIMITED — Capital/Financing Update 2012

Feb 2, 2012

==> picture [223 x 52] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

Probiomics Limited

ABN 97 084 464 193

Suite 1 A, Level 2 802 Pacific Highway Gordon NSW 2072

The Australian Securities Exchange Companies Announcements Office SYDNEY

P: +61 2 9844 5422 F: +61 2 9844 5445 W: www.probiomics.com.au

3 February 2012

Dear Sir/Madam

Extension of Public Offer Period

In accordance with the rights reserved under the Prospectus issued by Probiomics Limited ( Company ) and dated 21 December, 2011, the Company has decided to extend the Public Offer Period from Monday 6 February, 2012 at 4.00 p.m. (AEDST) to Monday 27 February, 2012 at 4.00 p.m. (AEDST).

Accordingly, the Company expects that the Public Offer will be completed in accordance with the following amended indicative timetable:

	Event	Originally	Amended Date
		Proposed Date
Close of Public Offer Period		6 February, 2012	27 February, 2012
	Issue of:
•	Public Offer Shares and Public Offer Options;	19 March, 2012	Unchanged
•	Bid Consideration, being Consolidated Probiomics
	Shares and Replacement Probiomics Options; and
•	Director Options and Probiomics Performance
	Executive Options
Share Consolidation takes effect		21 March, 2012	Unchanged
	Completion of dispatch of new holding statements	28 March, 2012	Unchanged
	to all Probiomics Securityholders to reflect:
•	issue of Probiomics Securities (see row 2 above); and
•	changes in holdings of Probiomics Securities as a
	result of the Share Consolidation
Change in Probiomics’ name to “Bioxyne Limited”		30 March, 2012	Unchanged
becomes effective

Page 1

==> picture [223 x 52] intentionally omitted <==

As at the date of this announcement, it is not proposed to alter the date of any Event as stated in the “Important Dates” at the commencement of the Bidder’s Statement issued by the Company and dated 13 December, 2011, other than the closing date of the Public Offer Period.

However, the Company reserves the right to vary the date of any Event referred to in the “Important Dates”, including the date of any of the Events referred to in the table immediately above.

Yours sincerely,

==> picture [101 x 46] intentionally omitted <==

ASHOK JAIRATH

Company Secretary

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[® ]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.

Page 2